RxDoctor Payments Data

Channaiah Srikanth Mysore

Neurology · Salisbury, MDNPI 1881900652

Payments from drug & device makers

$5,287in general payments, 2019–2025

Across 344 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$817
  • Biogen$363
  • UCB, Inc.$335
  • Novartis$325
  • SK Life Science, Inc.$314
  • EMD Serono, Inc.$298
  • plus $3K from 41 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$5,25899%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,287 in reported general payments places this provider in the 55th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$94,235
Medicare patients
383
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a11$90,924
CopaxoneGlatiramer Acetate13$74,300
VimpatLacosamide25$46,686
SympazanClobazam18$37,044
BriviactBrivaracetam17$29,915
Emgality PenGalcanezumab-Gnlm33$27,694
FycompaPerampanel19$24,027
Lacosamide143$21,069
Levetiracetam449$11,747
Dimethyl Fumarate11$4,866
Carbamazepine ErCarbamazepine28$4,552
DepakoteDivalproex Sodium11$4,452
Oxcarbazepine68$4,205
DilantinPhenytoin Sodium Extended14$3,222
Zonisamide134$3,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$363$90,92411 claims
UCB, Inc.Vimpat, Briviact$335$76,60142 claims
Teva Pharmaceuticals USA, Inc.Copaxone$280$74,30013 claims
Aquestive Therapeutics, Inc.Sympazan$62$37,04418 claims
Eisai Inc.Fycompa$229$24,02719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 442 neurology providers in Maryland.

Other neurology in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →